New 9-Month pill regimen could tackle Drug-Resistant TB
NCT ID NCT07268664
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a 9-month, all-oral combination of four drugs (BLMZ) for people aged 12 and older with rifampicin-resistant tuberculosis. The goal is to see if this shorter regimen leads to a cure without the need for injections. Participants take the pills daily or weekly and are followed for 24 months to check for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BLMZ regimen (Bedaquiline, Linezolid, Moxifloxacin/Levofloxacin, Pyrazinamide)
- What this could lead to
- If successful, this could provide a shorter, all-oral treatment option for rifampicin-resistant tuberculosis, potentially improving cure rates and reducing treatment burden.
- What could go wrong
- This is a single-arm trial with no comparison group, so results are compared to historical data. The regimen may cause side effects like nerve damage or liver issues, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center of Disease Prevention and Control in Kashi Area
Kashgar, Xinjiang, China
-
Hetian Prefecture Infectious Diseases Hospital
Hetian, Xinjiang, China
-
The Third People's Hospital in Aksou
Aksu, Xinjiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new patient cohort unlock the secrets of TB treatment success?
- Shorter TB treatment: a 4-Month regimen put to the test
- Can immune profiling unlock the hidden stages of tuberculosis?
- Lung damage after TB: a new study tests whether rehabilitation can restore breathing and quality of life
- Can a more powerful antibiotic clear TB faster? a trial puts rifapentine to the test.
- Could a simple screening strategy uncover hidden TB in COPD patients?